Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03649074 · ClinicalTrials.gov registry record · NA

Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant

A NA study of Attention Deficit Hyperactivity Disorder, sponsored by Akili Interactive Labs.

Completed
Registry status
NA
Development phase
206
Enrollment target
2
Study locations

NCT03649074: Completed NA study of Attention Deficit Hyperactivity Disorder, sponsored by Akili Interactive Labs.

NCT03649074 is a NA study of Attention Deficit Hyperactivity Disorder that has completed, run by Akili Interactive Labs. The registered enrollment target is 206 participants, roughly in line with the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03649074, a NA study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Akili Interactive Labs.

COMPLETED
Registry status
NA
Development phase
206 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom tracking) in participants not recently on medication.

Primary Outcome

The Impairment Rating Scale (IRS) is a parent-rated scale that assesses individualized areas of impairment for a child participant and asks parents to make a rating of how significantly these problems impact functioning across a range of domains (social, family, school, self-esteem). Parents describe the primary areas of difficulty for each child and then provide a rating (via a Visual Analog Scale) of how much the difficulties affect the different areas of functioning ranging from (1) "no probl

Conditions Studied

Attention Deficit Hyperactivity Disorder

Interventions

  • DEVICE AKL-T01

Study Locations (2)

Arizona

  • Melmed Center - Scottsdale

Nevada

  • Center for Psychiatry and Behavioral Medicine - Las Vegas

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2018-12-28
Est. Completion 2019-09-23
Phase NA
Akili Interactive Labs

13 total trials

What the finished NCT03649074 record still lists

NCT03649074 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 215-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which AKL-T01 is the first listed.

NCT03649074 reports a single indexed study location in Arizona, Nevada.

Frequently Asked Questions

What is clinical trial NCT03649074 about?

NCT03649074 is a clinical study titled "Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant". The purpose of this study is to determine the effects of combining AKL-T01 (with AKL-X01 symptom tracking) as adjunctive treatment to stimulant medication, and to understand the effects of AKL-T01 treatment (with AKL-X01 symptom tracking) in participants not recently on medication.

What is the current status of trial NCT03649074?

This trial is currently completed. It is a NA study. The enrollment target is 206 participants. The study started on 2018-12-28. Estimated completion is 2019-09-23.

What conditions does trial NCT03649074 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT03649074?

The interventions under investigation include: AKL-T01 (DEVICE).

Who is sponsoring clinical trial NCT03649074?

This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03649074 being conducted?

This trial has 2 study locations across Arizona, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03649074's enrollment target sits among peer trials

206 33rd of 102 higher than 70 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03373968 · 206 participants · Phase 2

    Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

  • NCT03550391 · 206 participants · Phase 3

    Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • NCT04757116 · 206 participants · NA

    Post-Market Study to Assess iTind Safety in Comparison to UroLift

  • NCT05675865 · 206 participants · NA

    Cryoablation for Monomorphic Ventricular Tachycardia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03649074, the US trial registry maintained by the National Library of Medicine. NCT03649074 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.